Get notified when BLSM files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — The auditor's report includes a going-concern explanatory paragraph, and management has concluded substantial doubt exists about the company's ability to continue as a going concern.
  • Grade 4 Transaminitis (new) — Two new cases of severe liver enzyme elevation emerged after the data cut, one reported as a serious adverse event.
BLSM BLSM 424B4

BlossomHill Therapeutics prices IPO at $16.00/share, raising $150M gross; company nets $134.9M

Filed August 7, 2026 · ~2 min read

Key Changes

  • high

    BlossomHill is offering 9,375,000 shares at $16.00 per share, for gross proceeds of $150.0 million. After underwriting discounts and expenses, the company expects net proceeds of $134.9 million.

    The Offering verify on EDGAR →
  • high

    The company plans to use net proceeds primarily to fund clinical development: approximately $70.0 million for BH-30643, $20.0 million for BH-30236, and $15.0 million for BH-501284, with the remainder for general corporate purposes.

    Use of Proceeds verify on EDGAR →
  • high

    BlossomHill reported a GAAP net loss of $60.6 million for 2025, up from $30.7 million in 2024, and an accumulated deficit of $156.0 million as of March 31, 2026.

    Risk Factors verify on EDGAR →

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.

Partner

Trade BLSM commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify